Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like I*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000160 Incyte Corporation 09/30/2022 50881001060 Jakafi Oral Tablet 10 mg 60 Pack 07/01/2022 311.54 16200.00 06/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 09/30/2022 50881001560 Jakafi Oral Tablet 15 mg 60 Pack 07/01/2022 311.54 16200.00 06/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 09/30/2022 50881002060 Jakafi Oral Tablet 20 mg 60 Pack 07/01/2022 311.54 16200.00 06/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 09/30/2022 50881002560 Jakafi Oral Tablet 25 mg 60 Pack 07/01/2022 311.54 16200.00 06/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 09/30/2022 50881000560 Jakafi Oral Tablet 5 mg 60 Pack 07/01/2022 311.54 16200.00 06/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051330 Nitro-Dur Patch 0.1mg/hr 30 ct 04/11/2022 182.26 702.99 None Single Source Drug 520 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051430 Nitro-Dur Patch 0.2mg/hr 30 ct 04/11/2022 196.09 756.35 None Single Source Drug 398 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051530 Nitro-Dur Patch 0.3mg/hr 30 ct 04/11/2022 412.15 1589.73 None Single Source Drug 5100 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051630 Nitro-Dur Patch 0.4mg/hr 30 ct 04/11/2022 219.81 847.85 None Single Source Drug 284 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051730 Nitro-Dur Patch 0.6mg/hr 30 ct 04/11/2022 238.40 919.53 None Single Source Drug 291 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 06/30/2022 50742051830 Nitro-Dur Patch 0.8mg/hr 30 ct 04/11/2022 446.99 1724.12 None Single Source Drug 1908 None Increased API, overhead, expenses, and distribution costs causing need for price increase None No changes made None None None None None None None None None None None None
Rx0000287 Insmed Incorporated 03/31/2022 71558059028 AMIKACIN LIPOSOME INHALATION SUSPENSION EQ 590MG BASE/8.4ML (28 Vials) 01/01/2022 990.53 13372.21 05/15/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product developed in-house
Rx0000266 Intercept Pharmaceuticals, Inc. 03/31/2022 69516001030 Ocaliva (obeticholic acid) tablets 10mg 30ct 01/20/2022 448.18 8044.51 05/27/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000266 Intercept Pharmaceuticals, Inc. 03/31/2022 69516000530 Ocaliva (obeticholic acid) tablets 5mg 30ct 01/20/2022 448.18 8044.51 05/27/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054104005 Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml. 01/01/2022 502.00 5629.00 03/11/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054004301 Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml. 01/01/2022 111.00 2583.00 10/15/2036 Single Source Drug None 1 None 1 None 1 04/03/2017 Merrimack Pharmaceuticals None 1 For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf 1652.40 None 2015 1620.00 None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054112004 Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. 01/01/2022 412.00 9562.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054106004 Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. 01/01/2022 262.00 6088.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054109004 Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. 01/01/2022 349.00 8108.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054112003 Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. 01/01/2022 412.00 9562.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054109003 Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. 01/01/2022 349.00 8108.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2022 15054106003 Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. 01/01/2022 262.00 6088.00 03/08/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.